Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immuneering Corp

1.19
+0.09008.18%
Post-market: 1.220.0300+2.52%16:47 EDT
Volume:355.81K
Turnover:417.39K
Market Cap:42.71M
PE:-0.61
High:1.22
Open:1.13
Low:1.12
Close:1.10
Loading ...

Immuneering Is Maintained at Outperform by Oppenheimer

Dow Jones
·
07 May

Immuneering Corporation : Oppenheimer Cuts Target Price to $21 From $25

THOMSON REUTERS
·
07 May

Positive Outlook for Immuneering: Buy Rating Backed by Strategic Developments and Promising Clinical Data

TIPRANKS
·
07 May

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
06 May

Immuneering Q1 EPS $(0.42) Beats $(0.58) Estimate

Benzinga
·
06 May

Immuneering Corp - Extends Cash Runway Into 2026

THOMSON REUTERS
·
06 May

Immuneering Corporation Q1 EPS USD -0.42

THOMSON REUTERS
·
06 May

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
06 May

Immuneering Price Target Maintained With a $12.00/Share by Needham

Dow Jones
·
10 Apr

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
24 Mar

Immuneering Corp. Reports Promising Cancer Trial Results

TIPRANKS
·
22 Mar

Press Release: Immuneering Corporation Announces Grant of Inducement Award

Dow Jones
·
22 Mar

Immuneering Price Target Maintained With a $12.00/Share by Needham

Dow Jones
·
21 Mar

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Dow Jones
·
21 Mar

BRIEF-Immuneering Corporation Q4 Net Income USD 18.1 Million

Reuters
·
21 Mar

Immuneering Q4 EPS $(0.58) Misses $(0.46) Estimate

Benzinga
·
21 Mar

Immuneering Corp: Expects Its Cash Runway to Be Sufficient to Fund Operations Into 2026

THOMSON REUTERS
·
21 Mar

Immuneering Corporation Q4 EPS USD -0.58

THOMSON REUTERS
·
21 Mar

Immuneering Names DR. Igor Matushansky as Chief Medical Officer

THOMSON REUTERS
·
20 Mar

Press Release: Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Dow Jones
·
20 Mar